Echopoint secures £2.8m in seed funding to advance optical sensing heart technology
The funding round was led by UCL Technology Fund, Parkwalk, and Innovate UK to support sensor development and clinical trials.
Echopoint Medical is a London-based medical technology spinout developing optical sensing microcatheters to improve heart disease treatment.
Echopoint has secured £2.8m in a seed round led by UCL Technology Fund, Parkwalk, and Innovate UK. The capital will be deployed to refine the company's optical fibre sensors and technology platform, alongside completing a clinical trial involving up to 30 patients. The funding marks a significant step for the University College London spinout as it addresses diagnostic challenges in coronary heart disease treatment.
From the founder
"Coronary heart disease is endemic worldwide but far too often the decision to implant a stent is based on sub-optimal information. Our technology addresses the ‘grey zone’ of patients where the requirement for a stent is currently difficult to determine. By using advanced optical sensing technology, we hope to significantly improve the accuracy of current treatments, saving healthcare costs and preventing unnecessary operations for patients that could be treated with medicines."
Adrien Desjardins
Chief Technical Officer at Echopoint Medical
Investor perspective
"Stents are an invaluable, cornerstone treatment but are risky to insert and not always the best course of action for a patient. Echopoint’s remarkable technology has the potential to transform heart disease diagnosis and treatment. We are very excited by the potential of their technology platform, which utilises the latest fibre optic sensing and imaging techniques borne out of UCL’s world leading academic research."
David Grimm
Investment Director, AlbionVC
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
Categories
About the company
Echopoint Medical
Echopoint Medical develops optical sensing microcatheters for heart disease diagnosis.